EUVIMEDSkopri EUVIMED
EUVIMED · CrossrefJournal

Lung Cancer

ISSN 0169-5002 · Elsevier BV

Latest articles

  1. Efficacy and safety of primary granulocyte colony-stimulating factor prophylaxis in patients with small-cell lung cancer receiving first-line platinum–etoposide plus a programmed death-ligand 1 inhibitor: A multicenter retrospective observational study (G-GUARD; TORG-TG2504)

    Shuhei Teranishi, Yuki Misumi, Takuma Ishihara, Yuta Yamanaka, Daiki Murata, Tomofumi Hirose, Ryosuke Ochiai, Kento Takagi, Yuko Higashi, Yusuke Hamakawa, Satoshi Ikeda, Naoki Furuya, Yoshiro Nakahara, Satoru Miura, Katsuhiko Naoki

    Published: 2026-12DOI: 10.1016/j.lungcan.2026.109671

  2. Coexistence of Osimertinib-Resistant and Osimertinib-Sensitive cell states in an EGFR-Mutant NSCLC model derived at osimertinib resistance

    Ilaria C. Chillico, Mariateresa Frascino, Giorgia Protopapa, Francesca Ruzzi, Elena Nironi, Francesca Giunchi, Damiano Pistone, Elisa Gruppioni, Annalisa Altimari, Marzia Rossato, Giacomo Lora, Francesco Agustoni, Mattia Lauriola, Andrea Ardizzoni, Patrick L.S. Michel, Sofia Fini, Pier-Luigi Lollini, Stefania Angelicola, Francesco Gelsomino, Arianna Palladini

    Published: 2026-12DOI: 10.1016/j.lungcan.2026.109680

  3. Characteristics and outcomes of patients with advanced or metastatic non–small cell lung cancer harboring a HER2-activating mutation: a real-world retrospective cohort study using a US clinico-genomic database

    Xiuning Le, Christos Chouaid, Fernando Lopez-Rios, Mei Sheng Duh, Maral DerSarkissian, Vadim Bernard-Gauthier, Jihong Zong, Zdravko Vassilev, Orsolya Lunacsek, Angela Lax, Andreas Schlicker, Rose Chang, Megan Pinaire, Naiyu Chen, Qayyim Said

    Published: 2026-11DOI: 10.1016/j.lungcan.2026.109677

  4. Durvalumab plus etoposide–platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARD

    Isamu Okamoto, Byoung Chul Cho, Sarah B. Goldberg, Jonathan W. Goldman, Adrianus J. de Langen, Zofia Piotrowska, Jonathan W. Riess, Helena A. Yu, M Rosario Garcia Campelo, Jeremy Cetnar, Yu Jung Kim, Silvia Novello, Yoshimasa Shiraishi, Helen Ambrose, Paul E. Smith, Kwan Ho Tang, Jonathan M. Lehman, Xiuning Le

    Published: 2026-08DOI: 10.1016/j.lungcan.2026.109501

Volumes

2026 · 6132025 · 6552024 · 4692023 · 4612022 · 4232021 · 5462020 · 6062019 · 5932018 · 5662017 · 4682016 · 4592015 · 4782014 · 5142013 · 6592012 · 6132011 · 5472010 · 4242009 · 6102008 · 3592007 · 4502006 · 5072005 · 1,8052004 · 3572003 · 1,5272002 · 3012001 · 2962000 · 1,0641999 · 2381998 · 2781997 · 1,3171996 · 8281995 · 1,2111994 · 1,5951993 · 5491992 · 2701991 · 1,1451990 · 3311989 · 4661988 · 511987 · 387

Għarfien li jaqbel max-xogħol tiegħek.

Minn bidu b’xejn u riċerka personali tal-letteratura sal-Research Suite sħiħa.

Ara t-tariffi →

Il-full texts kollha tal-pubblikaturi huma inklużi?

Le. Ir-referenzi biblijografiċi, l-astratti u t-testi sħaħ huma kontenuti differenti. Jekk test sħiħ huwiex disponibbli jiddependi mis-sors, Open Access u l-liċenzji eżistenti tiegħek. Pjan ta’ EUVIMED ma jissostitwix drittijiet addizzjonali tal-pubblikaturi.